United Therapeutics Stock Alpha and Beta Analysis
| UTHR Stock | USD 316.73 3.13 0.98% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as United Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in United Therapeutics over a specified time horizon. Remember, high United Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to United Therapeutics' market risk premium analysis include:
Beta 0.52 | Alpha (0.20) | Risk 2.31 | Sharpe Ratio (0.09) | Expected Return (0.21) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
United |
United Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. United Therapeutics market risk premium is the additional return an investor will receive from holding United Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in United Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate United Therapeutics' performance over market.| α | -0.2 | β | 0.52 |
United Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of United Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how United Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.United Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how United Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading United Therapeutics shares will generate the highest return on investment. By understating and applying United Therapeutics stock market price indicators, traders can identify United Therapeutics position entry and exit signals to maximize returns.
United Therapeutics Return and Market Media
The median price of United Therapeutics for the period between Wed, Dec 25, 2024 and Tue, Mar 25, 2025 is 357.64 with a coefficient of variation of 6.75. The daily time series for the period is distributed with a sample standard deviation of 23.53, arithmetic mean of 348.49, and mean deviation of 20.14. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 2500 shares by Michael Benkowitz of United Therapeutics at 111.0 subject to Rule 16b-3 | 12/26/2024 |
2 | Disposition of 7700 shares by Mahon Paul A of United Therapeutics at 163.3 subject to Rule 16b-3 | 01/02/2025 |
3 | Disposition of 600 shares by Michael Benkowitz of United Therapeutics at 367.8917 subject to Rule 16b-3 | 01/13/2025 |
4 | Disposition of 100 shares by Michael Benkowitz of United Therapeutics at 375.22 subject to Rule 16b-3 | 01/27/2025 |
5 | Disposition of 1142 shares by Michael Benkowitz of United Therapeutics at 345.6904 subject to Rule 16b-3 | 02/11/2025 |
6 | United Therapeutics Corporation A Cheap Biotech Stock to Invest In Now | 02/12/2025 |
7 | Disposition of 196 shares by Michael Benkowitz of United Therapeutics at 360.8488 subject to Rule 16b-3 | 02/14/2025 |
8 | Disposition of 400 shares by Michael Benkowitz of United Therapeutics at 373.6725 subject to Rule 16b-3 | 02/18/2025 |
9 | United Therapeutics Corp Reports Record Revenue Growth in 2024 | 02/26/2025 |
10 | United Therapeutics Full Year 2024 Earnings In Line With Expectations | 02/27/2025 |
11 | Disposition of 2500 shares by Thompson Tommy G of United Therapeutics at 175.43 subject to Rule 16b-3 | 02/28/2025 |
12 | Disposition of 137 shares by Michael Benkowitz of United Therapeutics at 318.8211 subject to Rule 16b-3 | 03/03/2025 |
13 | Ray Kurzweil Sells 15,000 Shares of United Therapeutics Corp | 03/04/2025 |
14 | Seizert Capital Partners LLC Has 14.19 Million Holdings in United Therapeutics Co. | 03/05/2025 |
15 | Disposition of 6550 shares by Mahon Paul A of United Therapeutics at 163.3 subject to Rule 16b-3 | 03/06/2025 |
16 | Disposition of 229947 shares by Rothblatt Martine A of United Therapeutics subject to Rule 16b-3 | 03/07/2025 |
17 | Disposition of 2000 shares by Michael Benkowitz of United Therapeutics at 111.0 subject to Rule 16b-3 | 03/10/2025 |
18 | Disposition of 200 shares by Michael Benkowitz of United Therapeutics at 317.1084 subject to Rule 16b-3 | 03/11/2025 |
19 | Disposition of 1520 shares by Michael Benkowitz of United Therapeutics at 360.7233 subject to Rule 16b-3 | 03/13/2025 |
20 | Is United Therapeutics Corporation the Best Healthcare Stock For Long-Term Investment | 03/14/2025 |
21 | Corsair Pharma Announces Successful Completion of Preclinical Program for Its Treprostinil Prodrug Transdermal System | 03/17/2025 |
22 | United Therapeutics Co. Short Interest Up 18.8 percent in February | 03/19/2025 |
23 | New York City Surgeon Presented with the Excellence in Kidney Transplantation Award | 03/21/2025 |
About United Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including United or other stocks. Alpha measures the amount that position in United Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | |
| Dividend Yield | 0.0129 | 0.0114 |
| Price To Sales Ratio | 5.54 | 5.27 |
United Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of United Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, United Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of United Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of United Therapeutics. Please utilize our Beneish M Score to check the likelihood of United Therapeutics' management manipulating its earnings.
| 28th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with United Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for United Stock Analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.